BioStock: Ultimovacs’ UV1 granted orphan drug designation

Ultimovacs has announced being granted Orphan Drug Designation by the FDA for its universal cancer vaccine UV1 in the treatment of malignant melanoma. The news comes barely one month after UV1 was granted Fast Track by the FDA, meaning that Ultimovacs’ candidate continues to solidify its stance as a promising cancer immunotherapy.

Read the article at biostock.se:

https://www.biostock.se/en/2021/12/ultimovacs-uv1-granted-orphan-drug-designation/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se